/

Sociétés

Fr

Non vérifié

Fresenius Kabi

Ce que nous écrivons

BiotechnologieIndustrieIndustrie pharmaceutiqueSantéSanté Publique

35 communiqués de presse

Voir tous les communiqués de presse

20/01/2026

Fresenius Kabi Recognized as a Top Employer in the United States for the Fourth Consecutive Year

Source

Émetteur

1.00

0

14/01/2026

Multimédia

Industrie

Hygiène alimentaire

Biotechnologie

Santé

Industrie pharmaceutique

Santé Publique

Oncologie

Marché du travail

Fresenius Kabi, TQ Therapeutics Announce Cell Therapy Technology Agreement

Source

Émetteur

1.00

0

06/01/2026

Fresenius Kabi Introduces New Presentation of Otulfi® (ustekinumab-aauz), a Biosimilar to Stelara®

Source

Émetteur

1.00

0

18/12/2025

Fresenius Kabi Introduces First-Ever Rocuronium Bromide Injection Stable at Room Temperature

Source

Émetteur

1.00

0

02/12/2025

Fresenius Kabi Expands Operating Room Portfolio with New Simplist® Prefilled Syringes

Source

Émetteur

1.00

0

24/11/2025

Fresenius Kabi Introduces Dalbavancin for Injection (for single-dose regimen use only)

Source

Émetteur

1.00

0

12/11/2025

Industrie

Médecine - Divers

Biotechnologie

Biologie

Santé Publique

Industrie pharmaceutique

Santé

Oncologie

Fresenius Kabi’s Adaptive Nomogram used on Aurora Xi Plasmapheresis System Now Operating Nationwide at BioLife Plasma Centers

Source

Émetteur

1.00

0

12/11/2025

CORRECTING and REPLACING Fresenius Kabi Issues Voluntary Nationwide Recall of Three Lots of Famotidine Injection, USP, 20 mg per 2 mL (10 mg per mL), 2 mL Fill in a 2 mL Vial Due to Out-of-Specification Endotoxin Results in Certain Reserve Samples

Source

Émetteur

1.00

0

07/11/2025

Fresenius Kabi Issues Voluntary Nationwide Recall of Three Lots of Famotidine Injection, USP, 20 mg per 2 mL (10 mg per mL), 2 mL Fill in a 2 mL Vial Due to Out-of-Specification Endotoxin Results in Certain Reserve Samples

Source

Émetteur

1.00

0

29/10/2025

Industrie

Biotechnologie

Hygiène alimentaire

Santé

Industrie pharmaceutique

Oncologie

FDA Grants Interchangeable Designation to Fresenius Kabi’s Biosimilars Conexxence® and Bomyntra® (denosumab-bnht)

Source

Émetteur

1.00

0

Followers

0

Compatibilité

0